AstraZeneca has announced promising results from the BATURA Phase IIIb trial, showcasing the effectiveness of AIRSUPRA ...

Topline results were announced from a trial evaluating albuterol/budesonide inhaler in patients with intermittent or mild persistent asthma.

UK-based pharmaceutical company AstraZeneca has reported that its Phase IIIb BATURA trial of Airsupra (albuterol/budesonide) ...

AstraZeneca’s BATURA phase IIIb trial of Airsupra in patients with intermittent or mild persistent asthma meets primary endpoint: Cambridge, UK Tuesday, October 8, 2024, 09:00 H ...

In the phase 3b BATURA trial, Airsupra—a pressurized metered-dose inhaler containing albuterol and budesonide—significantly ...

AstraZeneca's Airsupra (albuterol/budesonide) met the primary endpoint in the Phase III BATURA trial, significantly reducing ...

AstraZeneca’s inhaled rescue medication, Airsupra (albuterol/budesonide), has shown significant efficacy in reducing the risk of severe asthma exacerbations in patients with intermittent or mild ...

AstraZeneca's inhaled rescue medication, Airsupra (albuterol/budesonide), has shown significant efficacy in reducing the risk ...

The phase 3b BATURA study showed Airsupra (albuterol/budesonide) achieved a statistically significant reduction in the risk of severe asthma exacerbations when used as needed for rescue therapy ...

(Alliance News) - AstraZeneca PLC on Monday said an independent data monitoring committee recommended an early trial stop for its medication Airsupra due to overwhelming efficacy at pre-planned ...

2 All asthma prevalence estimates were calculated using post satisfaction weights unless otherwise indicated 3 Post stratification weights were not available from these countries, so sampling ...

Their analysis shows that children's risk of developing asthma later in life can be more reliably predicted by observing the dynamic development of symptoms during the first year of life.